WO2023148304 - METHODS AND APPLICATIONS OF ANALYZING THE PERFUSATE OF AN EX SITU PERFUSED KIDNEY
National phase entry is expected:
Publication Number
WO/2023/148304
Publication Date
10.08.2023
International Application No.
PCT/EP2023/052628
International Filing Date
03.02.2023
Title **
[English]
METHODS AND APPLICATIONS OF ANALYZING THE PERFUSATE OF AN EX SITU PERFUSED KIDNEY
[French]
PROCÉDÉS ET APPLICATIONS D'ANALYSE DU PERFUSAT D'UN REIN PERFUSÉ EX SITU
Applicants **
VIB VZW
Suzanne Tassierstraat 1
9052 Gent, BE
KATHOLIEKE UNIVERSITEIT LEUVEN
KU LEUVEN R&D
Waaistraat 6 - bus 5105
3000 Leuven, BE
Inventors
GHESQUIÈRE, Bart
Voerhoek 8
3061 Leefdaal, BE
JOCHMANS, Ina
c/o Campus Gasthuisberg
Herestraat 49
3000 Leuven, BE
Priority Data
22155190.6
04.02.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1192 | |
| EPO | Filing, Examination | 5239 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 4510 |
Total: 12107 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to the field of analyzing parameters in the perfusate of an organ under ex situ organ perfusion conditions. In particular the identified parameters include 1 or more of arginine, glutamate, glucose, glutamine, lactate, alanine, leucine and isoleucine; and are capable of accurately determining the extent of damage present in the perfused organ. Several applications of the assessment of these identified parameters are also part of the invention.[French]
L'invention concerne le domaine de l'analyse de paramètres dans le perfusat d'un organe dans des conditions de perfusion d'organe ex situ. En particulier les paramètres identifiés comprennent 1 élément ou plus parmi l'arginine, le glutamate, le glucose, la glutamine, le lactate, l'alanine, la leucine et l'isoleucine ; ils permettent en outre de déterminer avec précision l'étendue de lésions présentes dans l'organe perfusé. Plusieurs applications de l'évaluation de ces paramètres identifiés font également partie de l'invention.